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Dysregulated cholesterol metabolism is implicated in a number of
neurological disorders. Many sterols, including cholesterol and its
precursors and metabolites, are biologically active and important
for proper brain function. However, spatial cholesterol metabo-
lism in brain and the resulting sterol distributions are poorly
defined. To better understand cholesterol metabolism in situ across
the complex functional regions of brain, we have developed on-tissue
enzyme-assisted derivatization in combination with microliquid ex-
traction for surface analysis and liquid chromatography-mass spec-
trometry to locate sterols in tissue slices (10 μm) of mouse brain. The
method provides sterolomic analysis at 400-μm spot diameter with a
limit of quantification of 0.01 ng/mm2. It overcomes the limitations of
previous mass spectrometry imaging techniques in analysis of low-
abundance and difficult-to-ionize sterol molecules, allowing isomer
differentiation and structure identification. Here we demon-
strate the spatial distribution and quantification of multiple ste-
rols involved in cholesterol metabolic pathways in wild-type and
cholesterol 24S-hydroxylase knockout mouse brain. The technol-
ogy described provides a powerful tool for future studies of spa-
tial cholesterol metabolism in healthy and diseased tissues.
liquid chromatography-mass spectrometry | brain | cholesterol | 24S-
hydroxycholesterol | 24S,25-epoxycholesterol
The brain is a remarkably complex organ in terms of anatomyand function. Little is known about the landscape of the
metabolome or lipidome across the brain. The brain represents a
major repository of unesterified cholesterol in mammals; almost
25% of total body cholesterol is found in brain and the central
nervous system (CNS), where it is present at a level of about
20 μg/mg (wet weight) (1). As cholesterol cannot cross the blood
brain barrier (BBB) and be imported from the periphery, es-
sentially all cholesterol in brain is biosynthesized in brain. Inborn
errors of cholesterol biosynthesis often result in neurodevelopmental
disorders and retardation syndromes (2). It is recognized that not only
the steady-state level of cholesterol is critical for brain function but
also its constant turnover (3, 4). Much of brain cholesterol is found in
myelin sheaths of oligodendrocytes surrounding the axons of neurons
where it is turned over slowly (0.4% per day in mouse, 0.03% in
human) (1), but a more metabolically active pool of cholesterol is
located in intracellular structures such as the endoplasmic reticulum,
Golgi apparatus, and nucleus of neurons. Here turnover is estimated
at 20% per day in mouse (1). However, a precise map of cholesterol
turnover across the specialized functional regions of brain remains to
be generated.
Oxysterols are oxidized forms of cholesterol, or of its precur-
sors, and represent the initial metabolites in cholesterol catab-
olism (5). One of the most well-studied oxysterols in brain is
24S-hydroxycholesterol (24S-HC, see SI Appendix, Table S1 for
abbreviations and common and systematic names). In mammals
24S-HC is mostly synthesized in neurons by the enzyme cytochrome
P450 (CYP) 46A1 (cholesterol 24S-hydroxylase, CYP46A1) and
acts as a transport form of cholesterol (SI Appendix, Fig. S1) (4, 6,
7). Unlike cholesterol, 24S-HC can cross the BBB. The oxysterol
24S-HC is a ligand to the liver X receptors (LXRs) (8), the β-form
of which is highly expressed in brain (9), a potent modulator of the
N-methyl-D-aspartate receptors (NMDARs) (10), glutamate-gated
ion channels that are critical to the regulation of excitatory synaptic
function in the CNS, and it is also a modulator of cholesterol bio-
synthesis by interacting with the endoplasmic reticulum protein INSIG
(insulin induced gene) and restricting transport and processing of
SREBP-2 (sterol regulatory element-binding protein-2) to its active
form as a master transcription factor for cholesterol biosynthesis (11).
Despite its potent biological activity, little is known about levels of
24S-HC in distinct regions of brain (12, 13). This is also true of 24S,25-
epoxycholesterol (24S,25-EC), which is formed via a shunt pathway of
cholesterol biosynthesis in parallel to the Bloch pathway but without
the involvement of 24-dehydrocholesterol reductase (DHCR24, SI
Appendix, Fig. S1) (14, 15). The oxysterol 24S,25-EC has also been
shown to be formed from desmosterol by CYP46A1 in vitro (16). It is
a potent activator of the LXRs, inhibitor of SREBP-2 processing, and
also a ligand to the G protein-coupled receptor (GPCR) Smoothened
(SMO), a key protein in the Hedgehog (Hh) signaling pathway (8, 11,
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17, 18). The oxysterol 24S,25-EC has been shown to be important in
dopaminergic neurogenesis via activation of LXRs (19, 20).
The cholestenoic acids, 3β,7α-dihydroxycholest-5-en-(25R)26-oic
(3β,7α-diHCA) and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic
(7αH,3O-CA) acids, also formed by enzymatic oxidation of
cholesterol, are found in cerebrospinal fluid (CSF), the fluid
that bathes the CNS (21, 22). The acid 7αH,3O-CA has been sug-
gested to provide an export route for (25R)26-hydroxycholesterol
(26-HC, also called 27-hydroxycholesterol) which itself passes into
the brain from the circulation, but does not accumulate in brain (SI
Appendix, Fig. S1) (23, 24). The acid 3β,7α-diHCA has been shown to
be biologically active as a ligand to the LXRs and to be protective
toward oculomotor neurons (21). The location of the acid has not
previously been defined in brain (25).
To understand better the importance in brain of sterols in
general, and oxysterols in particular, it is necessary to correlate
molecular concentrations with histology. This can be achieved by
exploiting mass spectrometry imaging (MSI). MSI technology
mostly utilizes matrix-assisted laser desorption/ionization
(MALDI)-MS (26–29). MALDI-MSI has been used to image
lipids in brain (30–32); however, cholesterol and other sterols
tend to be poorly ionized by conventional MALDI and are un-
derrepresented in MALDI-MSI studies. To enhance ionization,
other desorption/ionization methods have been employed, in-
cluding nanostructure-initiator MS (33), sputtered silver-
MALDI (34), and silver nanoparticle-MALDI (35). These stud-
ies are mainly restricted to cholesterol. Alternatively, on-tissue
derivitization has been used to enhance MS ionization and to
image steroid hormones and steroidal drugs in tissue by exploiting
hydrazine reactions with carbonyl groups present in target analytes
(36–41). These derivatives have been used in combination with
MALDI and with liquid extraction for surface analysis (LESA)
technology, or with reactive-DESI (desorption electrospray ioni-
zation) (36, 42). Hydrazine derivatization is problematic for ste-
rols, oxysterols, or steroids not possessing a carbonyl group. To
address this issue, for in-solution analysis of oxysterols and sterols,
we and others have utilized a bacterial cholesterol oxidase enzyme
to specifically convert sterols with a 3β-hydroxy-5-ene structure to
a 3-oxo-4-ene and then derivatize the resulting 3-oxo group with
the Girard hydrazine reagent to provide a charge-tag to the target
molecule (Fig. 1) (43–45). This strategy is termed enzyme-assisted
derivatization for sterol analysis (EADSA). For comprehensive
analysis, oxysterols naturally possessing an oxo group, e.g.,
7αH,3O-CA or 7-oxocholesterol (7-OC, also called 7-ketocholesterol)
can be derivatized in parallel in the absence of cholesterol oxidase
(Fig. 1).
In the current study we describe how on-tissue EADSA with
microscale-LESA (μLESA) and liquid chromatography (LC)-MS
can be exploited for the localization of cholesterol, its precur-
sors, and metabolites, in rodent brain. The incorporation of on-
line LC is essential to separate isomers and also low-abundance
sterols from dominating cholesterol. We find 24S-HC to be the
most abundant oxysterol in all brain regions, being at the highest
levels in striatum and thalamus and at the lowest levels in gray
matter of cerebellum. The oxysterol 24S,25-EC is also abundant
in thalamus and sparse in gray matter of cerebellum. We are able
to definitively identify 3β,7α-diHCA in brain, where it is most
abundant in gray matter of the cerebellum. We confirm that 24S-HC
is almost completely absent from brain of the Cyp46a1 knockout
mouse (Cyp46a1−/−). The level of 24S,25-EC is reduced in the
Cyp46a1−/−mouse but low levels of 20S-hydroxycholesterol (20S-HC),
22R-hydroxycholesterol (22R-HC), 24R-hydroxycholesterol
(24R-HC), and 25-hydroxycholesterol (25-HC) are present in
this mouse.
Results
Development of the Analytical Platform.The platform was designed
to allow the localization by MS of cholesterol, its immediate
precursors, and of multiple oxysterols in tissue against a large
background of cholesterol and other more readily ionized lipids.
To meet this challenge, we have used on-tissue derivatization
(Fig. 1) in combination with μLESA and LC-MS with multistage
fragmentation (MSn). Each of the system components required
optimization as described below.
On-Tissue EADSA. The protocol for on-tissue enzymatic oxidation
of sterols (Fig. 1B) was adapted from the in-solution procedure
using cholesterol oxidase enzyme in KH2PO4 buffer (43, 45), the
only difference being that the enzyme was sprayed onto tissue
in buffer and then incubated at 37 °C in a humid chamber
(11.9 cm × 8.2 cm × 8.5 cm, 30 mL water), rather than being in
solution. In trial experiments, after a 1-h incubation period at 37 °C
there was no evidence for any nonoxidized sterol, as indicated by an
absence of peaks corresponding to [M+H]+, [M+Na]+, [M+K]+,
[M+H-(H2O)n]
+, [M+Na-(H2O)n]
+ or [M+K-(H2O)n]
+ of endog-
enous cholesterol or 24S-HC, or of added deuterated standards,
only of the 3-oxo-4-ene oxidation products (see also SI Appendix). The
next step in the method was on-tissue derivatization of oxo-
containing sterols using the Girard P (GP) hydrazine re-
agent (Fig. 1). Others have used Girard T (GT) hydrazine as the
derivatizing agent to react on-tissue with oxo-containing sterols/
steroids (36–41); however, based on our experience of using the
GP reagent for in-solution derivatization of oxysterols, GP hy-
drazine was preferred here (43, 45). A disadvantage of using GT
hydrazine is that a major MS2 fragment ion is the [M-59]+ species
([M-NMe3]
+) and the exact same neutral loss is observed in the
fragmentation of endogenous choline-containing lipids. With
[2H0]GP the major MS
2 fragment ion is [M-79]+ and for [2H5]GP
[M-84]+, neutral losses not common for other lipids (for further
details of fragmentations see refs. 25 and 43). We sprayed GP
reagent (6.3 mg/mL for [2H5]GP bromide) in the same solvent as
previously used for in-solution derivatization (70% methanol, 5%
acetic acid) (43, 45). As in reported studies using the GT reagent
(36, 37, 40), it was essential to incubate the GP-coated tissue in a
humid atmosphere to achieve efficient derivatization. Initial tests
in a dry atmosphere revealed no derivatization of 3-oxo-4-ene
substrates. Incubation in a humid chamber (12 cm × 12 cm ×
7.2 cm) containing 30 mL of 50% methanol, 5% acetic acid at
37 °C for 1 h provided an efficient derivatization environment with
minimum lateral dispersion of analytes (SI Appendix, Fig. S2).
Increasing the volume or organic content of solution led to lipid
delocalization, while reducing the volume and organic content
B
A
Fig. 1. Derivatization of oxysterols. (A) Derivatization of 7-OC with [2H0]
Girard P reagent ([2H0]GP) and of (B) 24S-HC with [
2H5]GP reagent following
enzymatic oxidation with cholesterol oxidase. For MSn fragmentation see
refs. 25 and 43 and SI Appendix, Fig. S9F.
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provided less efficient derivatization based on ion current in
μLESA-MS measurements.
μLESA. LESA is based on liquid microjunction surface sampling
(46), where solvent is deposited as a small volume liquid
microjunction by a robotic sampling probe, i.e., pipette tip or
capillary, onto a surface, aspirated back to the tip or capillary,
and the extract analyzed by electrospray ionization (ESI)-MS.
The LESAPLUS configuration of the TriVersa Nanomate incor-
porates a 200-μm internal diameter (i.d.)/360-μm outer diameter
(o.d.) fused silica capillary replacing the conventional pipette tip
(47), reducing the extraction spot size to ≤1 mm (48, 49).
However, when using a 50% methanol solvent, as required here
for extraction of derivatized sterols, we were unable to achieve
this spot size as the surface tension required for a stable liquid
microjunction was not attainable. To overcome this problem, the
sampling probe can be used to make a seal against the tissue
surface, thereby minimizing the possibility of solvent spreading
(50). We have attached a 330-μm i.d./794-μm o.d. FEP (fluori-
nated ethylene propylene) sleeve to the fused silica capillary and
used it to make a direct seal with the tissue surface, preventing
spreading of the extraction solvent beyond the boundary of the
sleeve (SI Appendix, Fig. S3A). This gave a spot size diameter
of ≤400 μm, as assessed by microscopic evaluation of tissue after
liquid extraction was performed in triplicate (SI Appendix, Fig.
S3B). A 50% methanol extraction solvent was chosen to closely
match the derivatization solvent. The volume of solvent dis-
pensed onto (more correctly, forced to be in contact with) tissue,
was optimized to maximize oxysterol extraction with an extraction
time of 30 s, as assessed by MS ion current for target oxysterols (e.g.,
24S-HC), without compromising spatial resolution, i.e., leaking of
solvent through the tissue–FEP seal. The number of repeat ex-
tractions on the same spot was similarly optimized. The optimal
conditions were a “dispensed volume” of 1 μL, an extraction time of
30 s, and performed three times on the same spot.
EADSA-μLESA-LC-MS. Previous studies using MS have defined
concentrations of 24S-HC, the major oxysterol in mouse brain, to
be of the order of 20 to 60 ng/mg (wet weight) (25, 51–53). For
comparison, the concentration of cholesterol is in the range of 10
to 20 μg/mg (1, 25, 52), and after EADSA treatment, in the absence
of chromatographic separation, cholesterol totally dominates the
μLESA-MS analysis of the mouse brain surface extract (Fig. 2A).
However, with the addition of LC to give the μLESA-LC-MS
platform, analysis of 400-μm diameter spot extracts of brain tis-
sue give clear separation of peaks corresponding to 24S-HC,
24S,25-EC, desmosterol, 8(9)-dehydrocholesterol (8-DHC), and
cholesterol (Fig. 2B). The 8-DHC is an enzymatically generated
isomer of 7-dehydrocholesterol (7-DHC), the immediate precursor
of cholesterol in the Kandutsch–Russell pathway (54).
We integrated μLESA with two different LC-MS systems: 1)
μLESA-LC-MS with a “conventional” flow rate of 200 μL/min,
and 2) μLESA-nano-LC-MS with a flow rate of 350 nL/min. Both
systems incorporate a microswitch and a reversed-phase trap
column prior to an analytical column which allowed trapping of
GP-derivatized sterols and washing to waste of unreacted GP re-
agent and more polar analytes (SI Appendix, Fig. S4 A and B). The
nano-LC-MS format gives a 10-fold improvement in sensitivity over
the conventional flow-rate LC-MS format, based on analysis of 24S-
HC, and is more suitable for the analysis of very low-abundance
oxysterols; however, it is susceptible to overloading by highly
abundant cholesterol. Both systems were utilized in this study to
cover the broadest range of sterols in brain.
Quantification Using On-Tissue Internal Standards. To quantify sterols
and oxysterols, isotope-labeled surrogates were sprayed on-tissue
providing known areal densities of internal standards. Initially, the
validity of using sprayed-on [2H7]24R/S-HC as an internal standard
for quantification of oxysterols was assessed by spraying both
[2H7]24R/S-HC and [
2H7]22S-HC onto six successive slices of
brain tissue at increasing concentration ratios of [2H7]24R/S-HC:
[2H7]22S-HC, but keeping the areal density of [
2H7]22S-HC constant.
A plot of peak area ratio of [2H7]24R/S-HC: [
2H7]22S-HC (averaged
over three closely arranged spots from the same isocortical region
on each slice) against areal density of sprayed-on [2H7]24R/S-HC,
gave a straight line with R2 > 0.999 (SI Appendix, Fig. S5A). When
this experiment was repeated but by plotting the peak area ratio of
[2H7]24R/S-HC: 24S-HC, where 24S-HC refers to the endogenous
molecule, against areal density of sprayed-on [2H7]24R/S-HC, for
closely arranged spots (n = 3) in the same region of interest, on six
successive slices, the result was a straight line of R2 > 0.994 (SI
Appendix, Fig. S5 B and C). Assuming the concentration of en-
dogenous 24S-HC does not vary across the six slices, or adjacent
spots within the same region of interest, the results indicate that
deuterated surrogates can be used as a reliable internal standard
for quantification of endogenous sterols.
To assess the reproducibility of the EADSA-μLESA-LC-MS
technology, adjacent spots (n = 6) in the isocortical region of a
single slice of mouse brain were analyzed. The mean value of
areal density of 24S-HC was determined to be 0.947 ± 0.078
ng/mm2 (mean ± SD), giving a % coefficient of variation (% CV)
of 8%. Assuming that the endogenous concentration of 24S-HC
did not vary across the six adjacent spots, the reproducibility of
the method is satisfactory. Reproducibility was further assessed
by analyzing nine regions of interest from four closely cut slices
from a single brain. The % CV for areal density in each indi-
vidual region varied from 12.4% for the striatum where the areal
density of 24S-HC was high (1.415 ± 0.176 ng/mm2, n = 4) to
46.3% in the white matter of the cerebellum where the areal
density of 24S-HC was low (0.191 ± 0.088 ng/mm2, n = 4, SI
Appendix, Fig. S6A). However, there is likely some contamina-
tion of white matter of the cerebellum by gray matter and vice
versa, accounting for the high % CV in these regions. Other than
for the cerebellum, the interslice reproducibility was deemed
acceptable. Similar analysis for cholesterol with conventional
LC-MS gave a value of 387.3 ± 14.6 ng/mm2 (% CV = 4%) for
five adjacent spots in the isocortex of a single tissue slice.
Cholesterol Metabolism in Different Regions of Wild-Type Mouse
Brain. Although cholesterol has been imaged in adult rodent
brain, its precursors and metabolites have not. To demonstrate
the potential of our platform and gain insight into spatial cho-
lesterol metabolism in brain, we quantitatively analyzed the
sterol distribution in nine regions of interest, i.e., isocortex,
striatum, thalamus, hippocampus, midbrain, pons, medulla, cer-
ebellum (gray matter), and cerebellum (white matter) using
μLESA-LC-MS with conventional-flow and nano-LC-MS for-
mats (Fig. 3).
Cholesterol is the most abundant sterol across the whole brain
but there are concentration differences between regions (Figs.
3A and 4A). Hierarchal cluster analysis separated the nine re-
gions into three groups (Fig. 4B), of which cholesterol is most
abundant in pons (575.5 ± 122.0 ng/mm2, n = 3 animals) and
white matter of the cerebellum (509.2 ± 83.0 ng/mm2) but least
abundant in hippocampus (252.9 ± 27.3 ng/mm2), gray matter of
cerebellum (263.3 ± 71.3 ng/mm2), and isocortex (305.1 ± 53.8
ng/mm2). Desmosterol, the immediate precursor of cholesterol
in the Bloch pathway, was found to be about two orders of
magnitude less abundant than cholesterol but its spatial distri-
bution correlated significantly with cholesterol (SI Appendix, Fig.
S7A). The areal density of desmosterol ranged from 4.212 ±
1.546 ng/mm2 in pons to 1.025 ± 0.356 ng/mm2 in the gray matter
of the cerebellum (Figs. 3B and 4C). We also detected 8-DHC in
our analysis (Fig. 2 B and E), which is an enzymatic isomeric
product 7-DHC, the immediate precursor of cholesterol in the
Kandutsch–Russell pathway (SI Appendix, Fig. S1) (54). The
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Fig. 2. μLESA-LC-MS(MSn) analysis following EADSA treatment of mouse brain. (A, Upper) Combined mass spectra recorded over the entire chromatogram,
from striatum of WT mouse brain. (A, Lower) Mass spectrum recorded at 17.03 min from the same brain region. The peaks at m/z 523.4398, 539.4354, and
546.4793 correspond to endogenous cholesterol, 24S-HC and [2H7]24S-HC internal standard, respectively. (B) RICs for the [M]
+ ion of endogenous cholesterol (m/z
523.4419 ± 10 ppm, Upper), dehydrocholesterols (521.4262 ± 10 ppm, second panel), 24S-HC (539.4368 ± 10 ppm, third panel) and 24S,25-EC (537.4211 ± 10 ppm,
Lower) from striatum of WT mouse brain. Peak intensities are relative to cholesterol but magnified as indicated. (C) RIC for the [M]+ ion of endogenous 24S-HC
(m/z 539.4368 ± 10 ppm) from striatum of WT brain (Upper) and of Cyp46a1−/−mouse brain (Lower). Peak intensities are normalized to the 24S-HC peak fromWT
mouse brain. ND, not detected. Note, 24S-HC appears as a doublet in chromatograms in B and C, this is a consequence of syn and anti conformers of the GP
derivative. (D) MS3 ([M]+→ [M-Py]+→) spectra recorded at 20.89 min and 20.88 min corresponding to endogenous cholesterol from two consecutive spots in the
striatum. (E) MS3 ([M]+ → [M-Py]+→) spectra recorded at 20.12 min corresponding to endogenous desmosterol (Upper) and 20.64 min corresponding to 8-DHC
(Lower) from striatum of WT mouse. (F) MS3 ([M]+ → [M-Py]+→) spectra recorded at 17.03 min corresponding to endogenous 24S-HC (Upper) and 17.37 min
corresponding to 24S,25-EC (Lower) from striatum of WT mouse. Note in the EADSA process 24S,25-EC isomerizes to 24-oxocholesterol.
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areal density of 8-DHC was consistently lower than that of
desmosterol in all brain regions measured, but its distribution
pattern is quite similar to that of desmosterol and cholesterol
(Figs. 3 and 4). These data indicate that the distributions of
cholesterol and its immediate precursors are correlated together
in brain (SI Appendix, Fig. S7A).
Cholesterol
160         ng/mm2 700
Desmosterol
0.4          ng/mm2 4.4
8-DHC
0.1          ng/mm2 1.1
24S-HC
0.08         ng/mm2 2.6
24S,25-EC
0.01         ng/mm2 0.25
Allen Brain Atlas Cyp46a1
Cerebellum
Medulla
Pons
ThalamusStriatum
Hippocampus
A D
B E
C F
G
Fig. 3. Sagittal section of a WT mouse brain analyzed by μLESA-LC-MS following EADSA treatment. A photograph of a tissue slice showing spots analyzed
with areal density, determined by μLESA-LC-MS, of (A) cholesterol, (B) desmosterol, (C) 8-DHC, (D) 24S-HC, and (E) 24S,25-EC. Areal density is color coded on a
blue-to-red scale as indicated. (F) Expression of Cyp46a1 (55). Image courtesy of © 2006 Allen Institute for Brain Science. Mouse Brain. Available from: https://
mouse.brain-map.org/experiment/show/532667. (G) Annotation of the different regions of mouse brain (55). Image courtesy of © 2006 Allen Institute for
Brain Science. Mouse Brain. Available from: http://mouse.brain-map.org/experiment/thumbnails/100042147?image_type=atlas.
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Fig. 4. Sagittal section of WT mouse brain analyzed by μLESA-LC-MS following EADSA treatment. Areal density (ng/mm2) of sterols in nine brain regions
from three WT mice and dendrograms from hierarchal cluster analysis for the brain regions averaged over the biological replicates (see Statistics section).
Areal density of (A) cholesterol, (C) desmosterol, (E) 8-DHC, and (G) 24S-HC. Significance levels from ANOVA using Tukey’s multiple comparison test are
indicated for those brain regions showing significant differences. *P < 0.05, **P < 0.01, ***P < 0.001. Values for individual mice are given by separate
histogram bars. The number of dots within each bar indicates the number of brain slices analyzed for each mouse. The dots within the bars correspond to
region average for each brain slice. The height of each bar represents the mean of the region average of each brain slice. The number at the bottom of each
bar indicates the total number of spots analyzed per mouse. The error bars indicate the SD of all of the spots per mouse. Dendrograms for (B) cholesterol, (D)
desmosterol, (F) 8-DHC, and (H) 24S-HC. A greater horizontal axis distance from zero indicates greater dissimilarity between different brain regions, whereas
a lower distance from zero indicates greater similarity between different brain regions.
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The major cholesterol metabolite in brain is 24S-HC, ac-
counting for around 50% of cholesterol turnover in the brain.
However, the distribution of 24S-HC is significantly different
across different brain structures (Figs. 3D and 4G), ranging in
areal density from 0.161 ± 0.024 ng/mm2 in the gray matter of
the cerebellum to 1.637 ± 0.159 ng/mm2 in the thalamus and
1.805 ± 0.158 ng/mm2 in the striatum. Remarkably, the distri-
bution of 24S-HC across the different brain regions does not
correlate significantly with levels of cholesterol or its precursors
(SI Appendix, Fig. S7A). Interestingly, while the level of 24S-HC
varies by a factor of about 10 across the different regions, the
corresponding variations of cholesterol and desmosterol are only
factors of about 2 and 4, respectively. The oxysterol 24S-HC is
formed from cholesterol by the enzyme CYP46A1 expressed in
neurons localized to multiple subregions of brain (6). In-
terrogation of the Allen Mouse Brain Atlas reveals that Cyp46a1
is highly expressed in striatum and thalamus but at lower levels in
the cerebellum (Fig. 3F) (55). Our results suggest that the pat-
tern of 24S-HC in brain reflects local Cyp46a1 expression.
Another oxysterol identified in brain is 24S,25-EC (Fig. 2 B
and F) (15). This oxysterol is not a metabolite of cholesterol, but
formed in parallel to cholesterol via a shunt pathway using the
exact same enzymes, but with the exclusion of DHCR24 (SI
Appendix, Fig. S1) (14). In cellular systems, the level of 24S,25-
EC reflects the activity of the cholesterol biosynthesis pathway.
Recent studies also suggests that 24S,25-EC can be formed
in vitro from desmosterol via a CYP46A1 catalyzed reaction
(16). We found 24S,25-EC to be present in all brain region but to
be particularly abundant in thalamus at an areal density of
0.158 ± 0.026 ng/mm2 (Figs. 3E and 5A). Factor analysis reveals
that 24S,25-EC correlates most closely with 24S-HC (SI Appen-
dix, Fig. S7A), although being about 10 times less abundant. The
distribution of 24S,25-EC in brain likely reflects the varying ac-
tivities of de novo cholesterol biosynthesis and of CYP46A1 in
the different brain regions.
While, cholesterol, desmosterol, 8-DHC, 24S-HC, and 24S,25-
EC can all be analyzed by EADSA-μLESA-LC-MS at conven-
tional flow rates, low-abundance oxysterols require the more
sensitive EADSA-μLESA-nano-LC-MS format. The nano-LC-
MS format provides a lower limit of quantification (LOQ) of
0.01 ng/mm2 based on a CV of <25% at the LOQ and a limit of
detection (LOD) of 0.001 ng/mm2 (SI Appendix, Fig. S5).
Previous studies have suggested that 26-HC is imported into
brain and converted in brain by a combination of enzymes,
CYP27A1, and CYP7B1 to 3β,7α-diHCA and further by
hydroxysteroid dehydrogenase (HSD) 3B7 to 7αH,3O-CA (SI
Appendix, Fig. S1) (21, 23, 24, 56). The acid 3β,7α-diHCA is a
ligand to the LXRs and is neuroprotective, while 7αH,3O-CA
lacks these activities (21). Using EADSA-μLESA-nano-LC-MS,
3β,7α-diHCA and 7αH,3O-CA are detected in brain. However,
using the EADSA method, 3β,7α-diHCA can be measured in
combination with 7αH,3O-CA, and at low levels the combined
areal densities of these two acids are measured more accurately
than either of the individual acids alone. The combination of
3β,7α-diHCA plus 7αH,3O-CA was evident at areal densities
ranging from close to the LOD, i.e., 0.002 ± 0.002 ng/mm2 up to
0.018 ± 0.009 ng/mm2 across the different regions of interest in
mouse brain (SI Appendix, Table S1). The combined acids were
found to be most abundant in the gray matter of the cerebellum,
although not statistically different from the white matter of the
cerebellum or isocortex (Fig. 5G and see also SI Appendix,
Table S1).
The oxysterol 7-OC can be formed from 7-DHC in a CYP7A1
catalyzed reaction (57), or alternatively, from cholesterol via free
radical-mediated reactions (58). As CYP7A1 is not expressed in
brain, free radical formation or import across the BBB are the
likely origins of this oxysterol in brain. The oxysterol 7-OC has
previously been detected in brain using Girard derivatization
(36). We find it to be distributed ubiquitously across the brain at
low levels (0.002 ± 0.002 to 0.004 ± 0.006 ng/mm2, see SI Ap-
pendix, Fig. S8).
Taken together, using EADSA-μLESA-LC-MS data we clearly
demonstrate that different brain regions have distinct sterol
patterns.
Locating Biologically Active Oxysterols in Cyp46a1−/− Mouse Brain.
Earlier studies have shown that although converting cholesterol
to 24S-HC by CYP46A1 is responsible for the majority of cho-
lesterol turnover in brain, the cholesterol content of whole brain
does not differ significantly between wild-type (WT) and
Cyp46a1−/− animals (52, 53, 59). This was explained by a re-
duction of cholesterol synthesis compensating for reduced me-
tabolism in the Cyp46a1−/− animals. As 24S,25-EC levels in brain
may reflect the combined activities of de novo cholesterol syn-
thesis and CYP46A1, we hypothesized that the levels of 24S,25-
EC are reduced in Cyp46a1−/− mice. Indeed, we found that the
level of 24S,25-EC decreased in all brain regions analyzed. In
particular, the areal densities of 24S,25-EC in the thalamus and
striatum of Cyp46a1−/− animals were reduced by about 80 to
90% compared to WT brain (Fig. 5 A and C and SI Appendix,
Table S1), while there was only about a 50% reduction in me-
dulla and cerebellum, demonstrating that a lack of CYP46A1
reduced 24S,25-EC in brain and that the thalamus and striatum
are the most affected areas. Notably, the dendrograms from hi-
erarchal cluster analysis are different in the two genotypes (Fig. 5
B and D).
In the WT mouse, the high areal density of 24S-HC (0.161 ±
0.024 to 1.805 ± 0.158 ng/mm2) compared to other oxysterols
makes the identification of minor (≤0.01 ng/mm2) and closely
eluting monohydroxycholesterols difficult. To overcome this
problem, we have taken advantage of brain tissue from the
Cyp46a1−/− mouse which is reported to be almost completely
devoid of 24S-HC (52, 53, 59). Analysis of the same brain regions
as for WT mouse confirmed an almost complete absence (≤0.001
ng/mm2) of 24S-HC in the Cyp46a1−/− animal (Fig. 2C and see
also SI Appendix, Table S1) but revealed minor amounts of 25-
HC (0.005 ± 0.002 to 0.023 ± 0.034 ng/mm2) and 24R-HC
(0.004 ± 0.002 to 0.023 ± 0.001 ng/mm2, SI Appendix, Fig. S9).
Although there was some variation in absolute concentrations in
different mice, 24R-HC was at the highest concentration in the
cerebellum of each mouse (Fig. 5E and see also SI Appendix,
Table S1) and 25-HC was more ubiquitously dispersed (SI Ap-
pendix, Fig. S8 and Table S1). Both of these oxysterols were
detected at low levels in an earlier study of homogenized
Cyp46a1−/− mouse brain, as was an unknown hydroxycholesterol
eluting later than the peaks of 24R-HC (52). Here we again
observe low levels of this oxysterol (0.007 ± 0.005 to 0.012 ±
0.006 ng/mm2) which we have previously assigned, based on re-
tention time and MS3 spectra, but in the absence of an authentic
standard, to be 12α-hydroxycholesterol (12α-HC, SI Appendix,
Fig. S9 A and E) (25).
Careful interrogation of the MS3 spectra recorded prior to the
elution of 25-HC indicate the presence of not only trace quan-
tities of 24S-HC (at about the limit of detection, SI Appendix,
Fig. S9 A and C), but also of the elusive 20S-HC (SI Appendix,
Fig. S9B) (60). The oxysterol 20S-HC gives a unique MS3 spec-
trum where the fragment ion m/z 327.2 is abundant (SI Appendix,
Fig. S9 B and F). By generating a multiple reaction monitoring
(MRM) chromatogram for the transition m/z 539.4 → 455.4 →
327.2, this oxysterol is highlighted (SI Appendix, Fig. S9A).
When the authentic standard of GP-derivatized 20S-HC was
spotted on mouse brain tissue, it eluted with an identical re-
tention time to the GP-derivatized endogenous molecule, and
the MS3 spectra of the standard and endogenous molecule are
almost identical. There are some small differences as a conse-
quence of partial coelution of isomeric oxysterols from tissue.
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However, an intense fragment ion at m/z 327.2 is unique to 20S-
HC. The oxysterol 20S-HC is a ligand of SMO and can activate
the Hh signaling pathway and has previously been reported in
only one prior publication, where it was found to be present in
rat brain and human placenta (61). Here we define its pres-
ence in mouse brain. Our data demonstrate that 20S-HC is
(Cyp46a1-/-)
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Fig. 5. Sagittal section of WT and Cyp46a1−/− mouse brain analyzed by μLESA-LC-MS following EADSA treatment. Areal density (ng/mm2) of sterols in nine
brain regions from three mice of each genotype and dendrograms from hierarchal cluster analysis for the brain regions averaged over the biological rep-
licates. Areal density of (A) 24S,25-EC, WT mouse; (C) 24S,25-EC, Cyp46a1−/− mouse; (E) 24R-HC, Cyp46a1−/− mouse; and (G) combined 3β,7α-diHCA and
7αH,3O-CA, in WT mouse. Statistical analysis and labeling is as described in Fig. 4. *P < 0.05, **P < 0.01, ***P < 0.001. Dendrograms for (B) 24S,25-EC, WT
mouse; (D) 24S,25-EC, Cyp46a1−/− mouse; (F) 24R-HC, Cyp46a1−/− mouse; and (H) combined 3β,7α-diHCA and 7αH,3O-CA, in WT mouse.
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ubiquitously distributed in brain regions at an areal density of
about 0.004 ± 0.003 to 0.007 ± 0.003 ng/mm2 in Cyp46a1−/− mice
(SI Appendix, Fig. S8 and Table S1).
As discussed above, the combined areal densities of 3β,7α-
diHCA and 7αH,3O-CA (SI Appendix, Fig. S8) can be measured
more accurately than either of the individual acids alone. In
agreement with the data for WT mice, the combined acids were
consistently most abundant in the gray matter of the cerebellum
of the Cyp46a1−/− mice (0.013 ± 0.014 ng/mm2, SI Appendix, Fig.
S8), although there was some mouse-to-mouse variation in
areal density.
Cholest-4-en-3-one has been found to be present in brain of
Alzheimer’s disease sufferers and at lower levels in control brain
samples (62). Here we detect cholest-4-en-3-one in all regions of
mouse brain at areal densities in the region of 0.156 to 0.318
ng/mm2 in bothWT and Cyp46a1−/− animals (SI Appendix, Fig. S8).
Application of MALDI-MSI for Cholesterol Analysis.As an alternative
to μLESA-LC-MS for the MS analysis of cholesterol, we have
explored the possibility of exploiting MALDI-MSI. Using on-tissue
EADSA in a similar manner to that employed with μLESA, it was
possible to image the [M]+ ion of GP-derivatized cholesterol (SI
Appendix, Fig. S10). There is good visual agreement between SI
Appendix, Fig. S10 and Fig. 4A.
Discussion
In the current work we have defined a methodology to locate
sterols, including cholesterol, its immediate precursors, and differ-
ent oxysterols in mouse brain using EADSA and μLESA-LC-MS.
This method compliments MALDI-MSI methods, also based on
EADSA, being concurrently developed for cholesterol imaging in
the W.J.G. and Y.W. laboratory in Swansea. The μLESA-LC-MS
method has a major advantage in that isomeric sterols and oxy-
sterols can be separated by LC, even at the stereochemical level,
something that has not been possible by any other separation de-
vices linked to MS. μLESA-LC-MS technology can be operated at
conventional LC flow rates for rapid analysis or on a nano-LC-MS
format to achieve high sensitivity for less abundant, but biologically
important oxysterols. Note, that although an oxysterol may be mi-
nor in concentration, the metabolic pathway of which it is an in-
termediate may be significant. The major oxysterol in brain is 24S-
HC (7, 63). Here we find 24S-HC to be most abundant in the
striatum and thalamus and least abundant in the cerebellum. Un-
surprisingly in the WT mouse, hierarchal cluster analysis for 24S-
HC reveals that striatum and thalamus cluster together, as do gray
and white matter of the cerebellum with pons and medulla (Fig.
4H). The oxysterol 24S-HC is formed from cholesterol by the en-
zyme CYP46A1 expressed in neurons localized to multiple subre-
gions of brain (6). Cyp46a1, is highly expressed in striatum and
thalamus but at lower levels in the cerebellum (Fig. 3F) (55), which
reflects the abundance patterns of 24S-HC, and partially of 24S,25-
EC, determined here by EADSA-μLESA-LC-MS. The agreement
between gene expression and enzyme product data evident here also
indicates that 24S-HC does not rapidly move into other brain re-
gions following its formation. In most studies, 24S-HC is analyzed in
whole brain homogenates being found at concentrations of 20 to 60
ng/mg (wet weight). Our values of 0.161 to 1.805 ng/mm (SI
Appendix, Table S1) translate to 16 to 176 ng/mg, assuming
efficient extraction from the 10-μm thick tissue sections and
minimal desiccation during tissue storage.
Cholesterol is the most abundant sterol in brain, being two to
three orders of magnitude more abundant that 24S-HC. In the
absence of derivatization, or chelation with Ag+, cholesterol can
be difficult to detect in MSI experiments (29). However, following
EADSA, cholesterol provides the most intense signal in MS
analysis of brain tissue (Fig. 2A). Cholesterol is found to be most
abundant in the pons and white matter of the cerebellum (Figs. 3A
and 4A); unsurprisingly, these two regions group together according
to hierarchal cluster analysis (Fig. 4B). Desmosterol, the immediate
precursor of cholesterol in the Bloch pathway is most abundant in
pons, as is 8-DHC, the isomer of 7-DHC the immediate precursor
of cholesterol in the Kandutsch–Russell pathway (Figs. 3 B and C
and 4 C and E). Factor analysis by sterol to sterol correlates
cholesterol, desmosterol, and 8-DHC most strongly (SI Appendix,
Fig. S7A). On the other hand, 24S-HC correlates most strongly
with 24S,25-EC. It is noteworthy that CYP46A1 generates 24S-
HC from cholesterol and 24S,25-EC from desmosterol, providing
one of the two pathways to biosynthesis of 24S,25-EC. Factor
analysis clusters pons and white matter of the cerebellum together,
reflecting their high abundance of cholesterol and its precursors (SI
Appendix, Fig. S7B). Similarly, thalamus and striatum cluster together,
reflecting the abundance of 24S-HC and 24S,25-EC.
It is interesting to compare the distribution of sterols and the
more abundant oxysterols with the expression of genes coding for
their biosynthetic enzymes, as detailed in the Allen Mouse Brain
Atlas (55). The Allen Mouse Brain Atlas (55) shows high expression
in pons of 3-hydroxy-3-methylglutaryl-CoA synthase 1 (Hmgcs1),
stearol-C-5 desaturase (Sc5d), Dhcr24, and dehydrocholesterol re-
ductase 7 (Dhcr7), coding a key enzyme in the early part of the
cholesterol biosynthesis pathway and three of the final enzymes in
the pathway, respectively. There is also comparatively weak ex-
pression of Cyp46a1, coding cholesterol 24S-hydroxylase, in pons
(55), which in combination can explain the elevated abundance of
cholesterol in this region. According to the Allen Mouse Brain Atlas
the expression of Cyp27a1, the gene coding the enzyme required to
introduce a hydroxy and then a carboxylate group at C-26 of cho-
lesterol, is of highest expression in the cerebellum (55), which is in
agreement with data generated here, finding cholestenoic acids to be
most abundant in cerebellum (Fig. 5G).
A point of consideration is whether residual blood in the ex-
cised brain tissue may undermine MS studies. For mouse brain it
is estimated that the residual blood content can be of the order
of 1% (mL/g) of the wet weight of brain (64). Taking data from
ref. 25, the concentration of nonesterified 24S-HC in mouse
plasma is about 5 ng/mL and in homogenized brain about 25 μg/g,
so a small amount of residual blood should have little or no
effect on MS data. This should also be true for cholesterol where
the respective concentrations for the nonesterified molecule are
200 μg/mL and 20 mg/g, and also for 24S,25-EC (1 ng/mL cf 1 μg/g)
(25). Further evidence against residual blood impacting on the data
presented here, is that neither nonesterified 26-HC, abundant in
mouse plasma (10 ng/mL), or 3β-hydroxycholest-5-en-(25R)26-oic acid
(4 ng/mL) (25) were detected in eitherWT orCyp46a1−/−mouse brain
by MS. However, in cases where the sterol concentrations in plasma
are much higher than those determined in brain, as may be the case
with plant stanols and sterols, data must be interpreted with caution.
The oxysterol 24S-HC is by far the most abundant oxysterol in
mouse brain (25, 52, 53). This makes analysis of closely eluting
low-abundance isomers challenging. However, deletion of
Cyp46a1 removes the biosynthesis of 24S-HC almost completely
and, with implementation of nano-LC-MS, allows measurement
of other isomers and oxysterols (52). In the current study we
were able to image 24R-HC, the epimer of 24S-HC, which is
found to be of most abundance in cerebellum (Fig. 5E) and to
detect other isomers, including 12α-HC, 25-HC, and the elusive
20S-HC (SI Appendix, Fig. S8). The 22R-HC was also found in
some analysis but at the limit of detection. The enzymes required
to biosynthesize 24R-HC and 20S-HC from cholesterol are un-
known. The enhanced abundance of 24R-HC in cerebellum of
the Cyp46a1−/− mouse does suggest CYP27A1 to be the relevant
cholesterol hydroxylase, but 24R-HC is present in brain of the
Cyp27a1−/− mouse arguing against this (25). CYP3A11 is a sterol
24R-hydroxylase and could perhaps convert cholesterol to 24R-HC
in brain. Cyp3a11 is, however, predominantly expressed in cortex
(55). CYP11A1 is the cholesterol 22R-hydroxylase required for
neurosteroid biosynthesis and has been shown to be expressed in
Yutuc et al. PNAS Latest Articles | 9 of 12
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mouse brain (65). It first hydroxylates cholesterol at position C-22R,
then at C-20, then cleaves the bond between these two carbons to
generate pregnenolone. Besides being the enzyme responsible to
generate 22R-HC from cholesterol, it may also be the catalyst for
formation of 20S-HC from cholesterol, although evidence for this
suggestion is lacking. There is only one previous report of the iden-
tification of 20S-HC in rodents or human (61). However, 20S-HC is
of considerable biological interest being a ligand to the GPCR SMO,
an integral receptor protein in the Hh signaling pathway, important
for determining cell fate during development (66–68).
The spatial resolution and spot size available with the μLESA
format (400-μm spot diameter), is admittedly inferior to that
available with MALDI-MSI (<50-μm laser spot diameter). How-
ever, μLESA can be coupled with LC, offering isomer separation,
essential for oxysterol analysis of tissue, where resolution of en-
dogenous oxysterols from those generated ex vivo by oxidation in
air is essential. MALDI can be linked with ion-mobility separation
and MSI, but in experiments performed to date, we have been
unable to separate different oxysterol isomers. A disadvantage
with the μLESA-nano-LC-MS format adopted here is the length
of chromatographic run time; this is however reduced by in-
creasing LC flow rate and column diameter from a nanoscale to a
more conventional scale (43, 45). However, increased flow rate
does come with the penalty of reduced sensitivity, due to the
concentration dependency of ESI. This is not an issue for cho-
lesterol, desmosterol, 8-DHC, 24S-HC, or 24S,25-EC but is for
less abundant oxysterols, where nano-LC-MS is more appropriate.
An alternative to μLESA is to use laser capture microdissec-
tion (LCMD) followed by conventional solvent extraction and
MS to localize sterols in tissue. Such an approach has been used
to investigate cholesterol localization in the retina using gas
chromatography-MS following a hydrolysis step (69), and for
total lipid analysis by shotgun lipidomics in mouse liver sections
(70). A similar approach could be used with in-solution EADSA
on captured tissue. However, as in all imaging experiments, the
achievable spatial resolution of LCMD-MSI is dictated by the
sensitivity of the analyzer for the target molecules. To achieve a
full oxysterol profile, LCMD-MSI is likely to offer comparable
results to μLESA-MS, but in the absence of robot-assisted
sample handling will be more labor intensive.
MALDI-MSI has been used to image cholesterol in rodent
brain with laser spot sizes of <50 μm but identification in MALDI-
MSI is often based on only an [M-H2O+H]
+ ion (71). However,
with the additional application of laser-induced postionization, to
give so called “MALDI-2,” sensitivity is sufficient to allow spot
sizes as small as 5 μm and the recording of confirmatory MS/MS
spectra (72). Superior spatial resolution can be achieved using
secondary ion mass spectrometry (SIMS) with spot sizes of 2 to
3 μm for the imaging of the [M-H2O+H]+ ion of cholesterol (73).
SIMS is often linked with time-of-flight (TOF) analyzers and using
TOF-SIMS, both cholesterol and cholesterol sulfate have been
imaged in skin at a resolution of a few micrometers (74, 75). Even
higher resolution (<0.1 μm) has been achieved with NanoSIMS to
map 18O isotope-labeled cholesterol in cells by monitoring the 18O
fragment ion (76). With respect to oxysterol analysis, however, it
should be noted that oxysterols are of 102 to 103 lower abundance
than cholesterol and exist as multiple positional, geometric, and
stereoisomers and have yet to be imaged by TOF-SIMS or by
MALDI with MS/MS.
In summary, application of EADSA with μLESA-LC-MS allows
spatial location of oxysterols and cholestenoic acids in mouse brain.
Through exploitation of theCyp46a1−/−mouse, where the biosynthesis
of 24S-HC is almost completely eliminated, other minor oxysterols are
revealed. To compliment EADSA-μLESA-LC-MS we are developing
EADSA in combination with MALDI-MSI. We find this ideal for
imaging cholesterol at high spatial resolution. EADSA-MS, on a
μLESA-LC-MS or MALDI-MSI format, will be a powerful tool to
study specific areas of healthy and diseased tissue. As a case in point, a
recent study shows that the expression of Cyp46a1 is decreased in the
striatum of a mouse model of Huntington’s disease (HD) and a gene
therapy aproach to induce the expression of CYP46A1 is suggested as a
potential treatment for HD (77). An immediate application of EADSA-
μLESA-LC-MS could be to assess the changes in 24S-HC, 24S,25-EC,
desmosterol, and cholesterol in pathological niches in animal models of
HD, and human postmortem tissues, and to monitor the production
and distribution of 24S-HC in brain as a result of adeno-associated virus-
mediated delivery of CYP46A1 into mouse striatum.
Materials and Methods
Experimental Design. The objective of the current study was to develop an
MS method suitable for the low-level quantitative determination of differ-
ent sterols and oxysterols, including cholestenoic acids, in different regions
of mouse brain. See SI Appendix, Materials and Methods for details of
chemical reagents and tissue sectioning. All animal experiments were
approved by Case Western Reserve University’s Institutional Animal Care
and Use Committee and conformed to recommendations made by the
American Veterinary Association Panel on Euthanasia.
Deposition of Internal Standard and On-Tissue EADSA. Frozen tissue sections
(10 μm) were dried in a vacuum desiccator for 15 min after which an internal
standard mixture of [2H7]24R/S-HC (5 ng/μL), [2H7]22S-HC (1 ng/μL), [2H7]22S-HCO
(1 ng/μL), in some experiments [2H7]22R-HCO (1 ng/μL), [2H7]cholesterol (20 ng/μL),
and [2H6]desmosterol (5 ng/μL), in ethanol, was sprayed from a SunCollect
automated pneumatic sprayer (SunChrom supplied by KR Analytical, Ltd) at a
flow rate of 20 μL/min at a linear velocity of 900 mm/min with a 2-mm line
distance and Z position of 30mm in a series of 18 layers. The resulting density of
the deuterated standard were 1 ng/mm2 for [2H7]24R/S-HC; 0.2 ng/mm
2 for each
of [2H7]22S-HC, [
2H7]22S-HCO, and [
2H7]22R-HCO; 4 ng/mm
2 for [2H7]cholesterol;
and 1 ng/mm2 for [2H6]desmosterol (SI Appendix, Materials and Methods). The
sprayer was thoroughly flushed with about 2 mL of methanol after which
cholesterol oxidase (0.264 units/mL in 50 mM KH2PO4, pH7) was sprayed for 18
layers. The first layer was applied at 10 μL/min, the second at 15 μL/min, and
then all of the subsequent layers at 20 μL/min to give an enzyme density of
0.05 m units/mm2. Thereafter, the enzyme-coated slide was placed on a flat dry
bed above 30 mL of warm water (37 °C) in a closed pipette-tip box (11.9 cm ×
8.2 cm × 8.5 cm) and then incubated at 37 °C for 1 h, after which, the slide was
removed and dried in a vacuum desiccator for 15 min. [2H5]GP (6.3 mg/mL
bromide salt, in 70% methanol with 5% acetic acid) was sprayed on the dried
slide with the same spray parameters as used for spraying cholesterol oxidase.
The resulting GP density was 1.21 μg/mm2. The slide was then placed on a flat
dry bed above 30 mL of prewarmed (37 °C) 50% methanol, 5% acetic acid in a
covered glass chamber (12 cm × 12 cm × 7.2 cm) and incubated in a water bath
at 37 °C for 1 h. The slide was removed and dried in a vacuum desiccator until
LC-MS analysis. To analyze sterols containing a naturally occurring oxo group,
the cholesterol oxidase spray step was omitted and [2H0]GP (5 mg/mL chloride
salt, in 70%methanol with 5% acetic acid) was used as the derivatization agent.
Further details of tissue handling and of MALDI-MSI experiments can be
found in SI Appendix, Materials and Methods.
Robotic μLESA. Derivatized oxysterols present in 10-μm thick slices of brain
tissue were sampled using a TriVersa Nanomate (Advion) with a modified
capillary extraction probe (LESAPLUS). The Advion ChipsoftX software was
used to capture an optical image of the prepared slide on a flatbed scanner
prior to analysis. The same software was also used to define extraction
points on the tissue prior to analysis. A 330-μm i.d./794-μm o.d. FEP sleeve
was attached to a 200-μm i.d./360-μm o.d. fused silica capillary held in the
mandrel of the Advion TriVersa Nanomate; this created a seal when in
contact with tissue, preventing the dispersion of extraction solvent (50%
methanol) and limiting the sampling area to the internal diameter of the
FEP sleeve (SI Appendix, Fig. S3 A and B).
Three microliters of extraction solvent was aspirated into the capillary from
the solvent reservoir (R1–R2 in SI Appendix, Fig. S4), the mandrel moved ro-
botically to an exact tissue location, and 1 μL of solvent “dispensed” on-tissue
and held for 30 s before being aspirated back into the capillary. The mandrel
moved once again, and the extract was dispensed into a well of a 384-well
plate. The process was repeated twice more with extract dispensed into the
same well, before the combined extract was injected via the extraction probe
into the sample loop of the LC system (see below). The entire procedure was
then repeated on a new extraction point. Multiple points were analyzed to
localize oxysterols across brain tissue.
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LC-MS(MSn) at Conventional Flow Rate. LC separations were performed on an
Ultimate 3000 UHPLC system (Dionex, now Thermo Scientific). The μLESA
extract was delivered from the sample loop onto a trap column (Hypersil
Gold C18 guard column, 3-μm particle size, 10 × 2.1 mm, Thermo Fisher Sci-
entific) using a loading solvent of 20% methanol at a flow rate of 50 μL/min.
The eluent from the trap column containing unreacted GP reagent was
delivered to waste (SI Appendix, Fig. S4A). After 10 min, the trap column was
switched in-line with the analytical column (Hypersil Gold C18 column, 1.9-μm
particle size, 50 × 2.1 mm, Thermo Fisher). At 11 min, 1 min after valve
switching, a gradient was delivered by the binary micropump-2 at 200 μL/min.
Mobile phase A consisted of 33.3% methanol, 16.7% acetonitrile, and
0.1% formic acid, and mobile phase B consisted of 63.3% methanol, 31.7%
acetonitrile, and 0.1% formic acid. The proportion of B was initially 20% and
was raised to 80% B over the next 7 min and maintained at 80% B for 4 min,
before being reduced to 20% B in 0.1 min, just after the trap column
switched off-line, and the analytical column was reequilibrated for 3.9 min.
After switching off-line at 22 min, the trap column was independently
washed with 10 μL of propan-2-ol injected from the Nanomate and de-
livered with mobile phase B at 200 μL/min for 6 min using micropump-1. At
26 min, the proportion of B washing the analytical column was raised from
20 to 80% over 3 min and held at 80% for a further 5 min before dropping
back down to 20% in 0.1 min and equilibrated for 4.9 min, ready for the
next surface extraction, giving a total run time of 39 min. At 29 min the trap
column was switched back in line with the analytical column and then out of
line at 34 min to check for the presence of any sterols retained by the trap
column. The gradients are illustrated in SI Appendix, Fig. S3 C and D.
For ESI-MS analysis the column eluent was directly infused into an Orbitrap
Elite mass spectrometer (Thermo Scientific) using a H-ESI II probe. To avoid
cross-contamination between samples, a blank injection of 6 μL of 50%
MeOH was performed with the same 39-min method between injections of
tissue extracts.
For each injection, five scan events were performed: one high-resolution
scan (120,000 full width at half maximum height definition atm/z 400) in the
Orbitrap analyzer in parallel to four MS3 scan events in the linear ion trap.
Quantification was by isotope dilution using isotope-labeled standard
spayed on-tissue. MS3 scans were for the transitions [M]+→ [M-Py]+→, where
Py is the pyridine group of the GP derivative. For details of nano-LC-MS(MSn)
see SI Appendix, Materials and Methods.
Quantification. To achieve reliable quantitativemeasurements, known amounts
of isotope-labeled internal standards [2H7]24R/S-HC, [
2H6]desmosterol, [
2H7]
cholesterol, and [2H7]22S-HCO were sprayed on-tissue prior to the EADSA
process. This procedure corrects for variation in derivatization efficiency,
surface extraction, extraction area, injection volume, and MS response.
Quantification was made from [M]+ ion signals in appropriate reconstructed
ion chromatograms (RICs). Approximate quantification of 20S-HC was per-
formed by utilizing the MRM [M]+ → [M-Py]+ → 327.2 transition and quanti-
fying against the transition [M]+ → [M-Py]+ → 353.3 for [2H7]24R/S-HC
(SI Appendix, Fig. S9F).
Statistics. For three WT mice, and separately for the three knockout mice,
unreplicated two-way ANOVA was performed with sterol areal density as
dependent variable and mouse and brain region as factors. The interaction
between mouse and brain region was used as error variance. The residuals
representing the interaction deviations were approximately normally dis-
tributed. Tukey’s multiple comparisons test was used to identify signifi-
cant differences between brain regions. Hierarchical cluster analysis using
between-groups linkage was used to represent differences and similarities
of average sterol areal densities between brain regions averaged across the
three biological replicates for each type of mouse, and with the differences
represented as squared Euclidean distances. The analyses were performed
using IBM SPSS Statistics 22 (IBM Corp) and GraphPad Prism 7.02 software
(GraphPad Software Inc). *P < 0.05, **P < 0.01, ***P < 0.001. Whiskers on
bar graphs represent 1 SD.
Data Availability. Datasets generated during this study are available in the
Open Science Framework repository under the identifier https://osf.io/vud84/.
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